Literature DB >> 9495670

Visceral leishmaniasis in patients infected with the human immunodeficiency virus.

F Laguna1, M Adrados, J Alvar, V Soriano, M E Valencia, V Moreno, R Polo, J Verdejo, M I Jiménez, P Martínez, M L Martínez, J M González-Lahoz.   

Abstract

The experience with 52 episodes of visceral leishmaniasis diagnosed in 43 patients is reported. The most common symptoms were fever (81%), splenomegaly (65%), hepatomegaly (63%), and pancytopenia (73%). In 79% of the patients, CD4+ cell counts were < 100 cells/mm3. Prior or simultaneous diagnosis of AIDS was made in 29 (67%) patients. Diagnosis was considered fortuitous in 19% of the episodes. In 27% of the episodes, the diagnosis was made on the basis of demonstration of parasites outside the reticuloendothelial system, chiefly blood (7 cases) and gastrointestinal mucosa (5 cases). Parasites were frequently observed or cultured from blood (22/37 episodes) or the digestive tract (8/9 episodes). High antimony doses were more effective than low doses in achieving clinical or parasitological cure (rate of cure, 80% vs. 40%, p = 0.11). Severe toxicity was observed in six (11.7%) of the 51 treated episodes. Severe AIDS-related diseases [odds ratio (OR) 10, p < 0.05] and CD4+ counts (OR 12, p < 0.05) were independent factors for early death. Prophylaxis with monthly pentamidine was not useful in reducing relapses of visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9495670     DOI: 10.1007/BF01700556

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis.

Authors:  S Matheron; A Cabié; F Parquin; C Mayaud; P Roux; M Antoine; C Chougnet; J P Coulaud
Journal:  AIDS       Date:  1992-02       Impact factor: 4.177

2.  Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.

Authors:  J A Pérez-Molina; R López-Vélez; P Montilla; A Guerrero
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

3.  Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients.

Authors:  R López-Vélez; F Laguna; J Alvar; J A Pérez-Molina; R Molina; P Martinez; J Villarrubia
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

4.  Prophylaxis of Pneumocystis carinii pneumonia.

Authors:  M Martinez; V Soriano; J González-Lahoz
Journal:  AIDS       Date:  1993-08       Impact factor: 4.177

5.  Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus.

Authors:  R Molina; C Cañavate; E Cercenado; F Laguna; R López-Vélez; J Alvar
Journal:  AIDS       Date:  1994-02       Impact factor: 4.177

6.  Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears.

Authors:  P Martínez; E de la Vega; F Laguna; V Soriano; S Puente; V Moreno; M J Sentchordi; C García-Aguado; J González-Lahoz
Journal:  AIDS       Date:  1993-02       Impact factor: 4.177

Review 7.  Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review.

Authors:  F Laguna; J García-Samaniego; V Soriano; E Valencia; C Redondo; M J Alonso; J M González-Lahoz
Journal:  Clin Infect Dis       Date:  1994-07       Impact factor: 9.079

8.  Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis.

Authors:  J E Conte
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

Review 9.  Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies.

Authors:  B L Herwaldt; J D Berman
Journal:  Am J Trop Med Hyg       Date:  1992-03       Impact factor: 2.345

10.  Visceral leishmaniasis and HIV-1 co-infection in southern France.

Authors:  E Rosenthal; P Marty; I Poizot-Martin; J Reynes; F Pratlong; A Lafeuillade; D Jaubert; O Boulat; J Dereure; F Gambarelli
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184

View more
  8 in total

1.  Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 2.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

3.  Asymptomatic carriers of Leishmania infantum in patients infected with human immunodeficiency virus (HIV) in Morocco.

Authors:  M Echchakery; J Nieto; S Boussaa; N El Fajali; S Ortega; K Souhail; H Aajly; C Chicharro; E Carrillo; J Moreno; A Boumezzough
Journal:  Parasitol Res       Date:  2018-02-24       Impact factor: 2.289

Review 4.  Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.

Authors:  Gláucia F Cota; Marcos R de Sousa; Tatiani Oliveira Fereguetti; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2013-05-02

Review 5.  Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.

Authors:  Gláucia F Cota; Marcos R de Sousa; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2011-06-07

6.  Risk Factors of Leishmania Infection among HIV-Infected Patients in Trang Province, Southern Thailand: A Study on Three Prevalent Species.

Authors:  Sakarn Charoensakulchai; Lertwut Bualert; Jipada Manomat; Mathirut Mungthin; Saovanee Leelayoova; Peerapan Tan-Ariya; Suradej Siripattanapipong; Tawee Naaglor; Phunlerd Piyaraj
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

7.  Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.

Authors:  Ermias Diro; Koert Ritmeijer; Marleen Boelaert; Fabiana Alves; Rezika Mohammed; Charles Abongomera; Raffaella Ravinetto; Maaike De Crop; Helina Fikre; Cherinet Adera; Robert Colebunders; Harry van Loen; Joris Menten; Lutgarde Lynen; Asrat Hailu; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2015-10-02

8.  Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.

Authors:  Ermias Diro; Tansy Edwards; Koert Ritmeijer; Helina Fikre; Charles Abongomera; Aderajew Kibret; Clélia Bardonneau; Peninah Soipei; Brian Mutinda; Raymond Omollo; Johan van Griensven; Eduard E Zijlstra; Monique Wasunna; Fabiana Alves; Jorge Alvar; Asrat Hailu; Neal Alexander; Séverine Blesson
Journal:  PLoS Negl Trop Dis       Date:  2019-02-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.